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Abstract
The rising incidence of diabetes mellitus (DM) worldwide presents a global 
public health problem. DM is classified into two main groups: type 1 (T1DM) and 
type 2 (T2DM). T1DM requires insulin treatment. T2DM is complex, heterogeneous, 
polygenic disease defined primarily by insulin resistance, ongoing hyperglycemia, 
and β cells’ dysfunction. For research in diabetes, an appropriate experimental 
model reflecting symptoms and complications of human T2DM is required for 
understanding the pathogenesis, molecular nature, and the possibilities of the 
treatment. Among the many animal models, rodent models that develop DM spon-
taneously are frequently used in the studies due to their similarity to the humans 
and economic effectiveness. This work gives a detailed overview of the literature, 
covering the characteristic of DM, its symptoms and complications, the description 
of Zucker diabetic fatty (ZDF) rats as an appropriate model for research in T2DM, 
and the possibility of the treatment.
Keywords: diabetes, animal model, pancreatic β cells, Zucker diabetic fatty rats, 
treatment
1. Introduction
1.1 Diabetes mellitus
Diabetes mellitus (DM) is often incident endocrine disorder in many countries 
[1]. The International Diabetes Federation reported that 6 million people die 
directly from diabetes every year, and additional 318 million people are  
suffering with DM. This number is predicted to reach 642 million by 2040 [2] and 
693 million by 2045 [3]. DM is a heterogeneous group of chronic disease character-
ized by a relative or absolute lack of insulin resulting in hyperglycemia [4]. It causes 
a variety of complications as cardiovascular disease, renal failure, neuropathy, and 
retinopathy [5]. Chronic hyperglycemia mostly deteriorates the vascular tree and 
promotes the development of micro- and macrovascular disease [6]. It was reported 
that hyperglycemia accelerates the development of DM complications through 
some mechanisms such as increased aldose reductase-related polyol pathway flux, 
formation of advanced glycation end products (AGEs), increased hexosamine 
pathway flux, activation of protein kinase C isoforms, and rising generation of 
reactive oxygen species [7]. Metabolic imbalance in the peripheral nervous system 
that is activated in the diabetic milieu of hyperglycemia, impaired insulin signaling, 
and dyslipidemia are the key parameters in the development of diabetic neuropa-
thy [8]. The determining points involve multiple mechanisms of glucose toxicity 
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including polyol pathway activity, hexosamine pathway, nonenzymatic glycations 
of proteins, and altered protein kinase C activity [9]. Activation of these pathways 
can eventually flow into inflammatory and oxidative stress in neurons and adjacent 
microvascular system [10].
DM is divided into two main forms—type 1 and type 2 [4]. Type 1 diabetes mel-
litus (T1DM) or insulin-dependent diabetes mellitus (IDDM) is an autoimmune 
disease and is a result of β cells’ death, because a foreign protein is incorporated 
into islet β cells. In response, lymphocytes attack the foreign protein and unwill-
ingly destroy β cells as collateral damage. It causes an absolute insulin deficiency 
[11]. It is uncertain what activates the autoimmune response, but some environ-
mental factors as toxins, viral infections, and psychosocial inputs are thought to 
play a plumbless role [12].
Historically, the usual ratio for T1DM to T2DM has been 1:20. Now it is chang-
ing because of expressive increase in the incidence of T2DM in children and young 
people [11].
1.2 Diabetes mellitus type 2
Type 2 diabetes mellitus (T2DM) or non-insulin-dependent diabetes mellitus 
(NIDDM) is a syndrome of β cells’ dysfunction including relative insulin deficiency 
associated with insulin resistance [11] and compensatory increases in insulin 
secretion [13]. It is associated with incorrect sensing of glucose signals by the β 
cells. T2DM is linked to a stage of insulin resistance. Insulin secreted by the β cells 
and bound to liver, muscle, and fat cells is subnormally efficacious in carrying out 
its metabolic action [11]. Generally, T2DM is characterized by the incapability of 
the pancreatic β cells to secrete appropriate quantities of insulin in order to offset 
hyperglycemia arising from peripheral insulin resistance and increases hepatic glu-
cose output [14]. It is a multifactorial and complex disorder [13] that is estimated to 
affect more than 100 million people worldwide [15]. About 80% of all people with 
diabetes suffer from T2DM [16]. Insulin resistance alone is insufficient to cause dia-
betes. A progression to overt diabetes required β cells’ failure as well [16–18]. Insulin 
resistance is associated with decrease in insulin receptors in target tissues (muscle, 
fat, or liver) and insulin receptor kinase activity that causes decrease in glucose 
transporter 4 (GLUT 4) translocation due to impaired signaling [19]. The onset 
of T2DM is preceded by an expressive increase in the plasma levels of free fatty 
acids (FFA) and by sixfold rise in triglyceride (TG) concentration in the pancreatic 
islets [20]. Chronic exposure to high glucose level and rising FFA concentration is 
detrimental to β cell function. This situation results in weak glucose-induced insulin 
secretion and rising level of apoptosis [21].
In spite of the increasing number of T2DM, little is known about the prevention 
of the disease and its complications at early stages [22]. In this stage insulin-sensitive 
tissue such as adipose tissue and skeletal muscle become insulin resistant. This causes 
the development of impaired glucose tolerance, and it can occur over a few years [23].
The pathogenesis of T2DM is complex and is primarily related to gene varia-
tion, external and internal environmental factors, abnormal protein modifications, 
oxidative stress, epigenetic effects, and energy metabolism disorders [24]. It was 
revealed that also the gut microbiota has been recognized as a key contributor to 
T2DM, and T2DM is linked to dysbiosis of the intestinal microbiota [25].
1.3 Obesity in type 2 diabetes
Onset and development of T2DM is commonly incurred by several factors, 
which are combined with lifestyle, obesity, genetic defects, virus infection, and 
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drugs [16]. Obesity is defined as a pathological excess of body fat that results from 
a permanent positive energy balance [26]. Persistent positive energy balance is 
pertinent to increased storage of triglycerides. This expands the adipose depots 
and increases the proportion of hypertrophied adipocytes [27]. Under condi-
tion of obesity, the lipid storage capacity of adipocytes is overcome, resulting 
in adipocyte-derived fatty acids and cytokines leaking into the circulation [28]. 
Damaging lipid species accumulates in ectopic tissue causing local inflammation 
and provides lipotoxicity [29]. Lipotoxicity determines an important link between 
obesity, insulin resistance, and T2DM. It interprets the harmful cellular effects of 
chronically increased concentrations of fatty acids and excess lipid accumulation 
in tissues other than adipose tissue. Excess adiposity is considered to promote the 
onset and severity of insulin resistance, contributing to emergence and progression 
of impaired glucose tolerance and T2DM [27].
Obesity-induced insulin resistance accelerates pancreatic islet exhaustion and 
thus the onset of T2DM [13]. Generally, obesity is a major risk factor for develop-
ing T2DM [30]. High-fat diet applied in animal’s model that has inclination to DM 
results in obesity, hyperinsulinemia, and altered glucose homeostasis due to insuf-
ficient compensation by the islets [31]. Whereupon it is required in human popula-
tion suffering T2DM to follow diet regimes and restriction of energy in the food so 
to maintain glucose concentration in acceptable level. In this case the diet has more 
considerable impact on diabetic primary complications than genetic predisposition 
[32]. Genetic disposition to obesity is probably commonly due to the small impinge-
ments of a wide selection of genes such as those encoding the beta3adrenoceptor, 
PPARγ and its co-activator-1, fat mass and obesity-associated gene, and adiponectin 
and a selection of genes that could potentially influence behavior and hypothalamic 
hunger-satiety mechanisms [33].
Currently, therapeutic strategies for T2DM are limited. They involve insulin and 
four main classes of oral antidiabetic agents in order to stimulate pancreatic insulin 
secretion. However, these agents suffer from generally inadequate efficacy and 
various adverse effects. So there is the possibility to try new therapeutic agents or 
treatments, most of them are under preclinical and early clinical stages [34].
2. Zucker diabetic fatty rats
An animal model for biomedical investigation is one in which normative biology, 
behavior, and pathological process can be studied and in which the phenomenon in 
one or more respects resembles the same phenomenon in humans [35]. Research in 
diabetes on humans is not possible or only partially possible. Hence, animal model 
of DM is very useful and advantageous [36]. Animal disease models are essential 
tools for studying the pathophysiology of DM enabling therapeutic interventions 
to be developed [37]. It is true that the present therapeutic approaches to treat 
DM and obesity, which are saving many lives every day, were invented, validated, 
and optimized on animal models [38]. When studying T2DM the use of an animal 
model with a homogenous genetic background is advised [39]. Most of the avail-
able models are based on rodents [36]. Rodents are most commonly utilized due to 
their small size, short generation interval, and easy availability [39] and because 
of economic consideration [36]. Being mammals, the physiology of rats is similar 
to humans than nonmammalian species [40]. Nevertheless, nonrodent models 
of diabetes are needed as a valuable supplement to rodents for both practical and 
physiological reasons with respect to humans [36]. Many animal models for DM 
research are obese, reflecting the human condition where obesity is closely related 
to T2DM development [41]. Animals exhibiting a syndrome of insulin resistance 
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and T2DM reflecting the human disease involve many species with genetic, nutri-
tional, or experimental causation [36]. There are a lot of rodent models available for 
the research in T2DM, but some of them may not always be satisfactory to mirror 
human T2DM due to the large heterogeneity in the latter. There are no fully unified 
classification criteria for this type of animal model. But, the spontaneous type 2 
diabetic rodent models are considered the most outstanding and most useful [42].
According to Srinivasan and Ramarao [36], spontaneous diabetic animal models 
have special advantages and also disadvantages. The advantages are:
a. The development of T2DM is of spontaneous origin involving genetic factors.
b. Animals develop characteristic features resembling human T2DM.
c. Most of inbred animal model in which the genetic background is homogene-
ous and environmental factors can be controlled allow genetic dissection of this 
multifactorial disease easy.
d. Variability of results is minimal and it required smaller sample size.
Among the disadvantages are mainly:
a. Highly inbred, homogenous, and mostly monogenic inheritance and development 
of diabetes are highly genetically determined unlike heterogeneity in humans.
b. Limited availability and expensive for the diabetes study.
c. Mortality due to ketosis problem is high in the case of animals with brittle pancreas 
and requires insulin treatment in later stage for survival.
d. Require sophisticated maintenance.
One of the rodent models that reflect human form of T2DM is Zucker dia-
betic fatty (ZDF) rats. ZDF rats as spontaneous diabetic animal model exhibit 
both the prediabetic and the end stage observed in human T2DM patients [43]. 
Spontaneously diabetic animals of T2DM may be acquired from the individuals 
with one or several genetic mutations transmitted from generation to generation or 
selected from nondiabetic outbred animals by repeated breeding through several 
generations. The result is that these animals inherited DM either as single or mul-
tigene defects. The metabolic particularities result from single gene defect (mono-
genic) which is due to dominant gene or recessive gene, or it can be of polygenic 
origin [36].
ZDF rats come from a colony of outbred Zucker rats in the laboratory of  
Dr. Walter Shaw at Eli Lilly Research Laboratories in Indianapolis (USA) during the 
years 1974–1975. In early 1981, some animals with diabetic lineage were designated 
and redefined. An inbred line of ZDF rats was established in 1985. Development 
to a genetic model was established in 1991 [44]. The Zucker fatty (ZF) rats carry a 
spontaneous mutation in the leptin receptor gene (fa) [45]. ZF rats resulted from 
the simple autosomal recessive (fa) gene on chromosome 5 [36]. This mutation 
causes hyperphagia, early onset of obesity, and insulin resistance [14] along with 
increased growth of subcutaneous fat depot [46]. At the age of 4 weeks, ZF rats 
gain weight more rapidly due to increased growth of subcutaneous fat depot, and 
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they have a noticeably higher body weight at about the age of 9 weeks [47]. The 
hyperphagia and obesity in ZF rats are attributed to hypothalamic defect in leptin 
receptor signaling that is related to mild hyperglycemia, mild glucose intolerance, 
insulin resistance, hyperlipidemia, and moderate hypertension [46]. ZF rats have 
impaired glucose tolerance rather than apparent diabetes [42].
Thereafter, a mutation in ZF strain led to a substrain with an evident diabetic 
phenotype—the Zucker diabetic fatty (ZDF) rats [42]. ZDF rats are less obese than 
ZF rats having a decrease beta cell mass which resulted in inability to compensate 
for severe insulin resistance [48]. The ZDF rats were derived by selective inbreeding 
of hyperglycemic ZF rats [49] within the first months of life due to leptin receptor 
defect and a genetically reduced insulin promoter activity [17]. ZF rats maintain 
normoglycemia despite their obese phenotype, hyperlipidemia, and hyperinsu-
linemia [42].
The ZDF male rats became an experimental model for type 2 diabetes mellitus 
(T2DM). They have a predictable progression from prediabetic to diabetic state 
[50]. The ZDF rats carry a genetic defect in β-cell transcription. It is inherited 
independently of the leptin receptor mutation and insulin resistance [17]. In predia-
betic stage of ZDF rats, there is no change in insulin mRNA levels. But, significant 
reduction (30–70%) of other islet mRNA levels, such as glucokinase, mitochondrial 
glycerol-3-phosphate dehydrogenase, voltage-dependent Ca2+ and K+ channels, 
Ca2+-ATPase, and transcription factor islet-1 may be detected [51]. It is known that 
FFA-induced suppression of insulin output in prediabetic stage of ZDF rats is con-
veyed by nitric oxide (NO) [52]. ZDF rats start to develop T2DM as early as 10 weeks 
of age, reaching 100% incidence at around 20 weeks of age [53]. It is possible to 
shorten prediabetic state and reach the symptoms of T2DM after high-energy diet. 
But, the animals receiving this diet are in the risky group because the diabetic state 
with its complications arrives quickly and rats can perish. In our experiment with 
ZDF rats, high-energy diet caused ketoacidosis that meant two cases of animal death 
in 7th week after initializing feeding with this caloric diet [54].
Blood glucose concentrations in ZDF rats usually increase from 7 to 10 weeks 
of age and impaired glucose tolerance at 5–7 weeks of age. At the age of 12 weeks, 
glucose intolerance becomes more severe than at 5–7 weeks of age [55]. Chronic and 
increasing hyperglycemia in ZDF rats is related to the loss of insulin and pancreatic 
duodenal homeobox (PDX-1) mRNAs. The lack of glucose stimulated insulin secre-
tion. The possible prevention of hyperglycemia could block the deficit in insulin 
amount and PDX-1 gene expression and improve insulin secretion [56].
Male ZDF rats that are homozygous recessive have nonfunctional leptin recep-
tors (fa/fa) and develop hyperlipidemia, obesity, and hyperglycemia. Rats that are 
homozygous dominant (+/+) or heterozygous (fa/+) are lean with normoglycemia. 
They are healthy, display no symptoms of diabetes, and are usually used as age-
match control rats in the experiments. In young fa/fa rats, insulin resistance appears 
which extends to a deployed insulin secretory defect that initiates hyperglycemia 
and inadequate β-cell compensation [17, 49]. The insulin resistance is a result of a 
mutant leptin receptor that causes obesity [17].
In ZDF rats, there are sex differences for phenotypes of diet-induced insulin 
resistance and glucose intolerance. The most affected are male individuals [57]. 
On normal diet, male rats from ZDF strain develop severe hypoinsulinemia 
and hyperglycemia by 4 months of age. Female individuals maintain normal 
level of blood glucose and insulin despite advanced obesity [38]. Female ZDF 
rats with fa/fa genotype become also obese and insulin resistant, but do not 
progress to hyperglycemia, except when fed a high-fat diet [58, 59]. The female 
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ZDF rats develop T2DM just on a diabetogenic diet [60]. Thus, male ZDF rats 
are widely used as animal models for human T2DM and diabetic nephropathy 
and neuropathy [58, 61]. Hyperglycemia in diabetic ZDF rats was recorded at 
2.5 month of age, and then blood glucose increased and reached an average value 
of 29.5 ± 0.9 mM at the age of 5 months. At the age of 5 months, fatty ZDF rats 
developed significant symptoms of thermal hypoalgesia indicated by prolonged 
response latencies in a tail-flick test. With progressing diabetes, the markers of 
thermal hypoalgesia increased at the age of 7 months and persisted till the 10th 
month [10]. The ZDF rats undergo a rapid transition between 10 and 15 weeks of 
age. At 10 weeks of age, they are insulin resistant, hyperlipidemic, and hyperin-
sulinemic. But, the high plasma insulin levels are insufficient to control glucose 
level, and the animals are hyperglycemic. Between 10 and 15 weeks of age, a loss 
in insulin secretory function occurs which leads to a marked decline in plasma 
insulin levels along with hyperglycemia [43]. The ability to secrete insulin to 
compensate peripheral insulin resistance is limited. β cells of ZDF rats are brittle 
and easily succumb to over-secretion pressure. The primary defect lies not in the 
ability of β cells to proliferate but rather in an enhanced rate of apoptosis. It shows 
impaired insulin secretory β-cell response to glucose, while it remains untouched 
to non-glucose secretogogues like arginine, a phenomenon similar to human 
T2DM. Downregulation of β-cell GLUT 2 transporters together with impaired 
insulin synthesis is probably responsible for hyperglycemia in ZDF animals. 
Decreased glucose transport activity and lowered GLUT 4 levels are present in  
the skeletal muscle and adipose tissue [34, 36, 48, 62]. Generally, it was reported 
that in the progression of ZDF rats, the decline of β-cell glucose transporter 2 
(GLUT 2) membrane receptors and the incidental loss of muscle glucose trans-
porter 4 (GLUT 4) are responsible for the impaired insulin secretion and sub-
sequent hyperglycemia. The activity of GLUT 4 receptors decreased in adipose 
tissue and skeletal muscle. This results in reduced β-cell transport ability together 
with the peripheral insulin resistance [50].
Siwy et al. [63] characterized the strain of ZDF rats as appropriate model for 
human disease based on urinary peptidomic profiles. In the study the diabetic rats 
were heavier than lean individuals. Consistent with a diabetic phenotype, ZDF 
rats were hyperglycemic and dyslipidemic already at early (2 months of age) and 
more severely at late (8 month of age). Renal function was markedly impaired 
at 8 months. Proteinuria was present at 2 months and progressively increased at 
8 months. At 8 months, ZDF rats’ renal histology showed pathological changes, 
including glomerular sclerosis with thickening of the Bowman capsule and retrac-
tion of the tuft, tubular atrophy and dilatation, and hyaline casts. Lean rats did 
not develop any histopathological changes. Chen and Wang [44] introduced the 
following pharmacologically related characteristics of ZDF rats: 25–55% reduc-
tion of GLUT 4 in the adipose tissue, heart, and skeletal muscle; loss of pancreatic 
duodenal homeobox gene expression; and free fatty acids and nitric oxide induced 
suppression of insulin output (Table 1).
Obesity of ZDF rats (fa/fa) is caused by hyperphagia [59], and food restriction 
can counteract or delay development of T2DM [55]. Hyperphagia leads to hyperin-
sulinemia, which upregulates transcription factors that stimulate lipogenesis. This 
results in ectopic deposition of triacylglycerol in non-adipocytes, thereby providing 
fatty acid substrate for pathological non-oxidative metabolism, such as ceramide 
synthesis [64].
The severity of DM in the adult hyperglycemic ZDF rats is reflected in body 
weight and food consumption [42]. High-energy diet in animal’s models inclined 
to DM leads to obesity, hyperinsulinemia, and altered glucose metabolism 
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because of insufficient compensation by the pancreatic islets [31]. In our experi-
ment [54] high-energy diet immediately induced hyperglycemia in ZDF rats, 
animals developed obesity, and we observed disturbance in some hematology 
parameters as neutrophils, mean platelet volume (MPV), and platelet count 
(PLT), which is a possible marker of angiopathy. In the groups of diabetic rats, 
we observed the significant weight decrease when compared to the control 
animals. It is probably linked to accelerated switch from prediabetic to diabetic 
state. It suggests the inability to utilize the calories consumed [42] and the 
degradation of structural proteins and muscle wasting in diabetic individuals 
[65]. Hempe et al. [59] found that body weight of ZDF obese rats was higher than 
the lean rats at the beginning of their study. Later, at around 16 weeks of age, 
body weight of obese animals started to decline. Lean rats reached the same body 
weight as obese rats at 25 weeks of age. The decrease of weight in obese diabetic 
rats on high energy is linked to accelerated switch from prediabetic to diabetic 
accomplished with associated complications of T2DM. Oyedemi et al. [65] 
explained this reduction in body weight as degradation of structural proteins and 
muscle wasting.
Hempe et al. [59] evaluated if nephropathy and neuropathy in ZDF rats are 
linked to the hyperglycemic state of the rats and are real diabetic late complica-
tions or are related to other characteristics of the fa/fa genotype. Good glycemic 
control may be effective in delaying the neuropathic symptoms in diabetic 
patients [66].
Main feature Characteristic Description
Type of 
diabetes
T2DM
• Characteristic features resembling 
human type
• Associated with obesity
• Hyperphagia
• Polyuria
• Polydipsia
• Hyperglycemia
• Hyperlipidemia
• Hyperinsulinemia
• Insulin resistance
• Reduction of GLUT 4 in adipose 
tissue
Development spontaneously involving 
genetic factors
Acceleration of symptoms by high-fat diet
Mortality due to ketosis after high-fat diet
Brittle pancreas
Genetic feature Leptin receptors
• Defect in leptin signaling
• Genetic defect in β cell transcription
• Insulin receptor deletion
Homozygous recessive (fa/fa) rats—
diabetic homozygous dominant (+/+) 
and heterozygous (fa/+) remain lean and 
normoglycemic
Using in 
research
Mechanism of T2DM
Obesity
Minimal variability of results, the 
possibility to use small size groups
Progression of 
diabetes
Insulin secretory defects
Inadequate β cell compensation
Predictable progression from prediabetic 
to diabetic state
Table 1. 
Major genetic, physiological, and pathophysiological characteristics of ZDF rats.
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2.1 Hematological parameters of ZDF rats
In general, diabetic patients have increased values of some hematological 
parameters as platelet count, mean platelet volume (MPV), and platelet distribu-
tion width (PDWc). Platelet activation can result in the generation of vascular 
disease [67]. Hematological parameters can be altered as a result of infection 
that occurs during DM [65]. In the human study, the total granulocyte count 
was increased in diabetic patients. It was confirmed that granulocyte count is 
associated with T2DM [68]. In our experiment significant increase in granulocyte 
count was also observed in diabetic ZDF rats in comparison with the control 
animals [54]. It was also published that increased count of one part of granulo-
cytes (neutrophils) correlated with the rising risk of vascular disease in T1DM 
[69] with consequences as diabetic angiopathy [70]. Mean corpuscular volume 
(MCV) and mean corpuscular hemoglobin (MCH) were decreased in the diabetic 
ZDF rats when compared to the lean control [54]. Similar results are published 
by Mahmoud [71] in white albino rats with experimentally induced DM and 
Oyedemi et al. [65] in streptozotocin-induced diabetic Wistar rats. Generally, 
the decrease of these hematological parameters during the diabetes could be an 
indicator of abnormal hemoglobin synthesis, failure of blood osmoregulation, 
and plasma osmolality [72].
Platelets play a critical role in atherogenesis and thrombosis-mediated myocar-
dial ischemia accelerated in diabetic state [73]. They are source of inflammatory 
mediators [74]. We observed increased values of platelets in diabetic ZDF rats 
against the lean control [54]. Through inflammatory process during the DM, the 
platelets are highly activated. Activated platelets presumably support neutrophil 
activation and recruitment through expressing selectins, inflammatory cytokines, 
and chemokines [75]. It was proven that platelets and neutrophils regulate and 
affect each other’s functions by platelet-leukocyte contact and releasing soluble 
effector mediators [76].
The marker of platelet function and activation is hematological parameter—
MPV [77]. Increased MPV can be an independent risk factor for arterial thrombotic 
events such as myocardial infarction and cerebral thromboembolism [78]. Usually 
diabetic patients have increased MPV values [79] correlated with a large thrombo-
cyte size that are more reactive and aggregable [77] which can upset hemostatic sys-
tem during the diabetic state [80]. In diabetes the risk of retinopathy onset increases 
with higher MPV [79, 81]. In our study diabetic ZDF rats had increased MPV values 
in comparison with the healthy lean control [54]. In diabetic patients there is usu-
ally higher value of PDWc—the hematological parameter that presents an indicator 
of variation in platelets’ size and activity [79, 82]. In our previous research [83], we 
observed that the rise in the secondary symptoms of T2DM complications caused 
by high-energy diet was accompanied with disturbed hematological parameters. It 
could be also a potential marker of angiopathy.
3. Other rodent models used in research in diabetes
Rodent animal models for investigation of T1DM are streptozotocin- or 
alloxan-induced animals, nonobese diabetic (NOD) mouse, and bio-breeding 
(BB) rat [84]. NOD mice and BB rats are rodent animal model with spontaneous 
development of T1DM [85]. Rodent models for T2DM include except ZDF rats 
also Goto-Kakizaki (GK) rats, Otsuka Long-Evans Tokushima Fatty (OLETF) rats, 
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spontaneously diabetic Tori (SDT) rats, Kuo Kondo (KK) mice, ob/ob+/+ mice, 
and db/db+/+ mice [84]. GK rats are nonobese Wistar substrain which develops 
T2DM early [86]. Male OLETS rats suffer from diabetes at 18–25 weeks of age. 
The symptoms include polyphagia, mild obesity, hypertriglyceridemia, hyperin-
sulinemia, and impaired glucose tolerance in 16 weeks of age [87]. Tori SDT rat 
is inbred strain of Sprague-Dawley rat. Male individuals have high glucose levels 
by 20 weeks, pancreatic islet histopathology, hemorrhage in pancreatic islets, and 
inflammatory cell infiltration with fibroblasts, prior to diabetes glucose intolerance 
with hypoinsulinemia [88].
KK mice are a polygenic model of obesity and T2DM. They are characterized 
by insulin resistance, hyperinsulinemia, and hyperphagia [89]. The ob/ob+/+ 
mice carry a mutation in the leptin gene, manifested as obesity, hyperglycemia, 
impaired glucose intolerance, and hyperinsulinemia [90]. The db/db+/+ mice have 
a leptin receptor mutation, are spontaneously hyperphagic, and suffer from obesity, 
hyperglycemia, hyperinsulinemia, and insulin resistance within the first month of 
life [91]. The advantages of ZDF rats in diabetes research are mainly due to the fact 
that it is a spontaneous model for T2DM research. It shows characteristics such as 
hyperglycemia, obesity, hyperphagia, polyuria, insulin disorders, and dyslipidemia 
due to the mutation in the leptin receptor gene and provides an appropriate model 
for common human T2DM. Moreover, these rats are calm and dispassionate; the 
handling and manipulation with them is comfortable.
4. Conclusion
The ZDF strain is of increasing preclinical interest due to its pathophysiologi-
cal similarities to human T2DM [92, 93]. They are generally used in studies of 
diabetes with obesity and cardiovascular complications because of dyslipidemia 
background [44]. Defective insulin release in ZDF rats could be partially restored 
by glucagon-like peptide (GLP-1). The action of GLP-1 therapy is mediated 
through Ca2+-independent signaling pathway in pancreatic islets [44]. The use of 
rosiglitazone protected ZDF rats against the loss of β-cell mass through sustain-
ing cell proliferation, and blocking increased β cells’ death [94]. Metformin 
prevented hyperglycemia in ZDF rats aged between 6 and 12 weeks. This com-
pound significantly reduced free fatty acid level and triglycerides. It delayed 
the onset of DM which is linked to the improvement in β cell functions, on a par 
with the lipotoxicity hypothesis for adipogenic diabetes [95]. Some experimental 
interventions provided on ZDF rats are shown in Table 2. In general, animal 
model for DM research is required and needed to uncover and understand the 
pathophysiology of disease. This is the key to the development of new therapies 
and treatment [96].
Today, the number of patients suffering from DM is increasing. The most 
common form of DM is T2DM. It is a genetic disease demonstrating insulin insuf-
ficiency. Therefore the research on this disease is deepening and required. Due 
to its complex, complicated, multifactorial heterogeneous disease resulting from 
both environmental factors and genetic responsiveness, accurate animal model 
that can mirror human T2DM symptoms and complication is required. Presently, 
the spontaneous T2DM rodent model for research in DM and obesity is ZDF rats. 
This strain shows characteristics such as obesity, hyperglycemia, insulin disorders, 
and dyslipidemia due to the mutation in the leptin receptor gene and provides an 
appropriate model for common human T2DM.
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Source Aim of the study Treatment Results and conclusion of the study
Tanaka 
et al. [97]
To assess if the use 
of antioxidants 
prevents glucose 
toxicity and 
ameliorates the 
progression of DM
6 weeks of age till 
12 weeks of age, 
antioxidants—N-
acetyl-L-cysteine, 
aminoguanidine, 
ZDF rats
• The treatment with antioxidants can 
partially prevent the progressive β 
cells’ dysfunction
Wasan 
et al. [43]
To examine the 
effect of organic 
vanadium 
compounds
3-week treatment 
with the insulin-
enhancing 
agent—vanadium 
compounds, ZDF
• Increase in plasma homocysteine 
and cysteine level
Hempe 
et al. [59]
If the complications 
in the kidney and 
nerves correspond 
to human diabetic 
complications
Food restriction 
or pioglitazone 
(peroxisome 
proliferator-activated 
receptor gamma 
- PPARγ agonist) 
treatment, ZDF rats
• Food restriction delayed (not 
prevented) the onset of DM for 
8–10 weeks and pioglitazone 
prevented the development of DM
• ZDF rat is a good model for diabetic 
nephropathy, but alterations 
in nerve functions were not 
diabetes-related
Siwy et al. 
[63]
Evaluation of the 
similarity between 
ZDF rats and 
T2DM in humans
24 hours study, ZDF 
rats 2 month and 
8 month of age
• ZDF rats may be more suitable to 
study the macrovascular branch 
within the pathophysiologic cascade 
of diabetic angiopathies, but it is 
not a good model for microvascular 
disease
Wang et al. 
[42]
Determination 
whether salsalate, 
a salicylate with 
anti-inflammatory 
properties, is 
effective in 
mitigating DM 
progression
Chronic 
administration of 
salsalate from 5 weeks 
of age to 24 weeks of 
age, ZDF rats
• The therapy is effective in particular 
animal model; it may only be effec-
tive in a subpopulation of humans 
with the disease
Kim et al. 
[98]
Investigation of 
therapeutic effect 
of resistance 
training on T2DM
8 weeks of resistance 
training, ZF and ZDF 
rats
• Regular resistance training initiated 
at the onset of DM improved glucose 
tolerance and GLUT 4 expression
Ďuračka 
et al. [99]*
Tvrdá et al. 
[100]*
The effect of 
bee bread on the 
oxidative profile of 
testicular tissue and 
fertility in diabetic 
rats
3 months therapy 
with bee bread in the 
dose of 250 mg/kg/
day, ZDF rats
• Significant increase of total 
antioxidant capacity of in testicular 
tissue lysate
• Bee bread effectively protected 
proteins against oxidative damage
• Bee bread provided substantial 
protection against testicular oxida-
tive stress
Soltesova 
Prnova 
et al. [10]
Observation 
of the effect of 
Cemtirestat on 
symptoms of 
peripheral diabetic 
neuropathy
2 months treatment 
with Cemtirestat in 
doses 2.5 and 7.5 mg/
kg/day, ZDF rats
• Partial inhibition of sorbitol 
accumulation in red blood cells and 
the sciatic nerve
• Decrease in plasma level of TBARS
• Normalization of peripheral 
neuropathy symptoms
Álvarez-
Cilleros 
et al. [101]
To examine 
potential 
antidiabetic 
properties of cocoa
10 weeks treatment 
with cocoa-rich diet, 
ZDF rats
• Improvement in glucose homeosta-
sis and insulin resistance, protection 
of renal structure and functionality
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Source Aim of the study Treatment Results and conclusion of the study
Capcarova 
et al. [102]*
To effect of bee 
bread on DM 
complications
4 months therapy 
with bee bread in the 
dose of 700 mg/kg/
day, ZDF rats
• Treatment of hyperglycemia, used 
as the prevention of DM in young 
age
*Experiments realized at the Department of Animal Physiology, Faculty of Biotechnology and Food Sciences, Slovak 
University of Agriculture in Nitra, Slovak Republic.
Table 2. 
The investigation of some therapeutic strategies in DM research using ZDF rats.
In general, in the future research, many novel strategies in treatment of DM will 
be surveyed, and the use of ZDF rats in these experiments will be worthy to study.
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